Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

By W. Scheuer, T. Friess, Helmut Burtscher, B. Bossenmaier, J. Endl, M. Hasmann. Cancer Research, 2009

618 citations recorded by the source corpus.

Subfields: Immunology and Allergy, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/2becc912811b2e0a9f6520c62dac9bac244c5b41

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Carlos L. Arteaga
2. M. Sliwkowski
3. L. Gianni
4. M. Lacouture

In Radiology, Nuclear Medicine and Imaging

1. Carlos L. Arteaga
2. M. Sliwkowski
3. M. Lacouture

Citations in the corpus

• Treatment of HER2-positive breast cancer: current status and future perspectives (2012, background): “In the randomized phase II CHERLOB trial, the activity of preoperative taxane–anthracycline chemotherapy in combination with trastuzumab, lapatinib, or combined treatment of trastuzumab and lapatinib was evaluated in patients with HER2-positive, stage II–IIIA breast cancer.58 For all arms, chemother”
• Antibodies and cancer therapy: versatile platforms for cancer immunotherapy (2010, background): “Synergistic antitumour effects of combination therapy with pertuzumab and trastuzumab have been reported in pre-clinical model”